Canaccord Genuity Maintains Buy on Ventyx Biosciences, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Ventyx Biosciences (VTYX) but lowers the price target from $20 to $16.

March 11, 2024 | 4:54 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Ventyx Biosciences but lowers the price target from $20 to $16.
While the reduction in price target from $20 to $16 by Canaccord Genuity could be seen as a negative adjustment, the maintenance of a Buy rating by analyst Edward Nash suggests a continued positive outlook on Ventyx Biosciences. This mixed signal might lead to a neutral short-term impact on VTYX's stock price as investors weigh the lowered price target against the reaffirmed confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100